Organization (Industry)
AMGEN INC.
ClinicalTrials.gov lists AMGEN INC. as lead sponsor of 1,066 trials, counting the companies grouped under it. AMGEN INC. itself has 538 active development programs and 177 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 44 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 48 in 2026 and about 49 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 5 trials are registered to start in 2027 or later.
Logo The original uploader was King of Hearts at English Wikipedia ., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers AMGEN INC. and 5 companies grouped under it: 1,066 lead-sponsored trials (1,043 its own, 23 in the grouped companies) and 17 legal-entity registrations (14 its own, 3 in the grouped companies).
Companies grouped under this page (5)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Five Prime Therapeutics (United States) | 11 | 1 |
| Amgen Research (Munich) GmbH | 10 | 0 |
| Horizon Therapeutics Ireland DAC | 1 | 0 |
| Viela Bio | 1 | 0 |
| Horizon Therapeutics (United States) | 0 | 2 |
Disease areas (373)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 92 |
| Multiple Myeloma | 89 |
| Psoriasis | 87 |
| Colorectal Neoplasms | 78 |
| Lymphoma | 77 |
Showing 5 of 373 disease areas.
Trials by start year as sponsor or collaborator (32)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 44 |
| 2025 | 50 |
| 2024 | 47 |
| 2023 | 35 |
| 2022 | 51 |
| 2021 | 60 |
| 2020 | 65 |
| 2019 | 84 |
| 2018 | 76 |
| 2017 | 68 |
Showing 10 of 32 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 71 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 845 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (538)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Maridebart Cafraglutide | Obesity | Phase 3 | 20 |
| Tarlatamab | Lung Neoplasms | Phase 3 | 14 |
| Tarlatamab | Small Cell Lung Carcinoma | Phase 3 | 13 |
| Maridebart Cafraglutide | Diabetes Mellitus | Phase 3 | 7 |
| Maridebart Cafraglutide | Diabetes Mellitus, Type 2 | Phase 3 | 7 |
Showing 5 of 538 active programs.
Approved assets (177)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Darbepoetin Alfa | 59 |
| DENOSUMAB | 54 |
| ETANERCEPT | 43 |
| Apremilast | 43 |
| Evolocumab | 40 |
Showing 5 of 177 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 49% hit target (n=284) | 39% on time (n=259) |
Journals published in (524)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 84 |
| The New England journal of medicine | 78 |
| Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 46 |
| The Journal of clinical endocrinology and metabolism | 37 |
| Circulation | 35 |
Showing 5 of 524 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2,660 | 526 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 36,751,000,000 | 7,711,000,000 | 7,272,000,000 |
| 2024 | 33,424,000,000 | 4,090,000,000 | 5,964,000,000 |
| 2023 | 28,190,000,000 | 6,717,000,000 | 4,784,000,000 |
| 2022 | 26,323,000,000 | 6,552,000,000 | 4,434,000,000 |
| 2021 | 25,979,000,000 | 5,893,000,000 | 4,819,000,000 |
| 2020 | 25,424,000,000 | 7,264,000,000 | 4,207,000,000 |
| 2019 | 23,362,000,000 | 7,842,000,000 | 4,116,000,000 |
| 2018 | 23,747,000,000 | 8,394,000,000 | 3,737,000,000 |
| 2017 | 22,849,000,000 | 1,979,000,000 | 3,562,000,000 |
| 2016 | 22,991,000,000 | 7,722,000,000 | 3,840,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (53)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-19 | Debt financing | 3,993,482,500 | Edgar offerings |
| 2026-02-17 | Other financing | not disclosed | Edgar offerings |
| 2026-02-17 | Debt financing | 3,961,495,000 | Sec extracted |
| 2026-02-13 | Follow-on offering | not disclosed | Edgar offerings |
| 2023-10-31 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 53 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 32 |
FDA recalls (12)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. | Class II | 2026-06-04 |
| Sensipar (cinacalcet) Tablets, 30mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC 55513-073-30 | Class II | 2026-06-04 |
| Sensipar (cinacalcet) Tablets, 60mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC 55513-074-30 | Class II | 2026-06-04 |
| Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60 | Class II | 2026-06-04 |
| Sensipar (cinacalcet) Tablets, 90mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, Made in Japan. NDC 55513-075-30 | Class II | 2026-06-04 |
Showing 5 of 12 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 17 | 2026-07-02 |
Manufacturing and distribution sites (5)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Amgen, Inc | Thousand Oaks, US | FDA, Health Canada | |
| Amgen Inc. | Louisville, US | EMA, FDA | |
| Amgen Inc. | New Albany, US | FDA, Health Canada | |
| Amgen Inc. | Boulder, US | Health Canada | |
| Amgen Inc. | Longmont, US | Health Canada |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (319)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 25 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 20 |
| Bristol Myers Squibb Co | Co sponsors trial with | 18 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 16 |
| Novartis Ag | Co sponsors trial with | 14 |
Showing 5 of 319 relationships.
Latest dated events (4,322)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-06-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 4,322 events.
CLIA clinical laboratory certificates (4)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| AMGEN INC | Certificate of compliance | Terminated |
| AMGEN INC | Certificate of waiver | Terminated |
| AMGEN (ARI) | Certificate of waiver | Terminated |
| AMGEN | Certificate of waiver | Terminated |
Biomarker capability evidence (4,457)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 4,457 evidence rows.
On Scientist.com
AMGEN INC. is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, and biomarkers this organization publishes on.
Work with ChemoCentryx, Inc. on Scientist.com
For prices, more details, or to contact ChemoCentryx, Inc., visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.